Table 3.

Summary of the case studies conducted recently.

Case Study Number	Condition	Sample Size	Notable Findings	Reference
1.	Post-COVID-19 complications—pulmonary edema	1	UCB mesenchymal cells reduce inflammation, including cytokine storms in COVID-19 patients, as indicated by decreased IL-4, IL-6, and IL-10 levels.	[65]
2.	COVID-19 with acute respiratory distress syndrome	24	Transfusing UCB stem cells safely increased patient survival to 91% (p = 0.015), and significantly improved recovery rates (0.03) by reducing cytokine storms.	[66]
3.	Autism spectrum disorder (ASD)	20	Administering UCB mesenchymal stem cells was safe and effective in improving ASD.	[67]
4.	Psoriasis	7	UCB MSC infusion had no side effects in 6 months of follow-up, increased Tregs and CD4+ memory T cells, and effectively treated 25% (2/8) and 66.7% (6/9) of male and female patients.	[68]
5.	Neurological disorders	100	UCB MSC administration for neurological disorders was safe and effective, with minimal side effects noted in one-year patient follow-up.	[69]
6.	Patients with muscular dystrophies	22	Two courses of 2–5 intravenous injections every two months significantly improved limb strength, stretching, bending, straightening, and gait (27.3%).	[70]
7.	Rats with skin wounds	-	UCB-MSCs assist in regenerating skin appendages, nerves, and arteries, aiding wound closure and controlling collagen distribution.	[71]
8.	Patients with alopecia lesions	3	No change was observed until day 53, and thereafter, minimal hair growth changes were detected in the first sample. The second patient showed significant hair growth on day 117 after transplantation By day 226, the third patient’s lesions had reduced, and they demonstrated remarkable hair growth.	[72]
9.	Acute Myeloid Leukemia (AML)	2963	Allo-HCT from an unrelated donor produces superior results to cord blood transplantation.	[73]